← All candidates
Eight insider buys in the last year — $13.32M in all.
39 filings on record.
CGEMCullinan Therapeutics, Inc.
NasdaqGS · Healthcare · $1.26B
$20.54
+0.69% · Sep 15
Eight insider buys in the last year — $13.32M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys● 24 sells◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.26B
Float
48.1M
78% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Lynx1 Capital Management LP
Bought $4.19M on Oct 9 — 626,043 sh @ $6.70, held indirect, 7.6% of their stake.
2 of 4 positions beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
33 more transactions on Pro →Context
Wall St
$31.55 avg target
+53.6% vs today · 11 analysts
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.75 act+$0.09
Q4 '25−$0.77 act+$0.07
Q3 '25−$0.77 act+$0.12
Q2 '25−$1.07 act−$0.21
Coverage
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset HopesSimply Wall St. · 06-23Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 dataMarketBeat · 03-14Cullinan Therapeutics: Q4 Earnings SnapshotAssociated Press Finance · 03-10
The file stays open
39 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice